Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring

被引:120
|
作者
Andrs, Martin [1 ,2 ]
Korabecny, Jan [1 ]
Jun, Daniel [1 ,2 ]
Hodny, Zdenek [3 ]
Bartek, Jiri [3 ,4 ]
Kuca, Kamil [1 ]
机构
[1] Univ Hosp Hradec Kralove, Biomed Res Ctr, Hradec Kralove 50005, Czech Republic
[2] Univ Def, Fac Mil Hlth Sci, Dept Toxicol & Mil Pharm, Hradec Kralove 50001, Czech Republic
[3] ASCR, Vvi, Inst Mol Genet, Dept Genome Integr, Prague 14220, Czech Republic
[4] Danish Canc Soc, Res Ctr, DK-2100 Copenhagen, Denmark
关键词
DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; TARGETING DNA-REPAIR; IN-VIVO EVALUATION; MAMMALIAN TARGET; ATAXIA-TELANGIECTASIA; (PI3K)/MAMMALIAN TARGET; PI3K/AKT/MTOR PATHWAY; BIOLOGICAL EVALUATION; SELECTIVE INHIBITOR;
D O I
10.1021/jm501026z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metabolism, migration, survival, and responses to diverse stresses including DNA damage. To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied. Despite their different nature, these two kinase families have related origin and share very similar kinase domains. Therefore, chemical inhibitors of these kinases usually carry analogous structural motifs. The most common feature of these inhibitors is a critical hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chemical tool for development of many additional PI3K and PIKK inhibitors. While several PI3K pathway inhibitors have recently shown promising clinical responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclinical development.
引用
收藏
页码:41 / 71
页数:31
相关论文
共 50 条
  • [1] Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
    Huang, Xueqin
    You, Li
    Nepovimova, Eugenie
    Psotka, Miroslav
    Malinak, David
    Valko, Marian
    Sivak, Ladislav
    Korabecny, Jan
    Heger, Zbynek
    Adam, Vojtech
    Wu, Qinghua
    Kuca, Kamil
    [J]. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01)
  • [2] Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
    Akinleye, Akintunde
    Avvaru, Parthu
    Furqan, Muhammad
    Song, Yongping
    Liu, Delong
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [3] Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs
    Verheijen, Jeroen C.
    Zask, Arie
    [J]. DRUGS OF THE FUTURE, 2007, 32 (06) : 537 - 547
  • [4] Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
    Akintunde Akinleye
    Parthu Avvaru
    Muhammad Furqan
    Yongping Song
    Delong Liu
    [J]. Journal of Hematology & Oncology, 6
  • [5] Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors
    Al Hasan, Mohammad
    Sabirianov, Matthew
    Redwine, Grace
    Goettsch, Kaitlin
    Yang, Stephen X.
    Zhong, Haizhen A.
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2023, 121
  • [6] Inhibition of phosphatidylinositol 3-kinase α (PI3Kα) prevents heterotopic ossification
    Antonio Valer, Jose
    Sanchez-de-Diego, Cristina
    Gamez, Beatriz
    Mishina, Yuji
    Luis Rosa, Jose
    Ventura, Francesc
    [J]. EMBO MOLECULAR MEDICINE, 2019, 11 (09)
  • [7] Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
    Margaret A. Knowles
    Fiona M. Platt
    Rebecca L. Ross
    Carolyn D. Hurst
    [J]. Cancer and Metastasis Reviews, 2009, 28 : 305 - 316
  • [8] Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
    Knowles, Margaret A.
    Platt, Fiona M.
    Ross, Rebecca L.
    Hurst, Carolyn D.
    [J]. CANCER AND METASTASIS REVIEWS, 2009, 28 (3-4) : 305 - 316
  • [9] ALPELISIB Phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor Oncolytic
    Heymann, M-F.
    Renema, N.
    Heymann, D.
    [J]. DRUGS OF THE FUTURE, 2015, 40 (04) : 213 - 223
  • [10] Phosphatidylinositol 3-kinase (PI3K) signaling and regulation of the antibody response
    Omori, Sidne A.
    Rickert, Robert C.
    [J]. CELL CYCLE, 2007, 6 (04) : 397 - 402